[PAGE 1]
(6)

Under separate cover,we are forwarding you 2 çm of 1-(betadiethylaminoethyl)-2-(p-ethoxybenzy1)-5-nitrobenzinicazole methane sulfonate (Pa-2068L, NIH-7607, ARC I-G-2). This is an extrenely potent materiai and care should be used in handling it; source was, of course, the Ciba company.

Also enclosing copy of a preliminary report on the addictiveness of two benzimidazole derivatives which was prepared for Dr. Nathan B. Eddy, Secretary of the Drug Addiction Committee. You will note this report indicates that Ba-2068h is 60 to 100 tines as potent as morphine orally in man. Good morphine-like effects were obtained with a total dose of 0.25 mg. Dr. Fraser is to explore the dose range, particularly the higher dose range, using the oral route. He will also study parenteral administration.

Detaiied pharmacological information is not yet available, however Ciba has indicated to me that they are preparing a brcchure for clinical investigators which will contain all the information. When this is received it will be copied and sent to you.

Kindest personai regards,

Yours very sincerely,

Harrinbeee

Harris Isbeli, M. D. Director

Hbs ples wuebedeng a prileminary rpaet iu Croes? talrouce bekeveid aspond pritoeybui

10t

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

PUBLIC HEALTH SERVICE

9 June 1959

Natleonl Zastituta of Mentai Rasith Aadictten Revearcd Cratet U.S. Publis Health Serviee Hesgitai Leciagion, Restucky

B-279